Company intelligence
Telix Pharmaceuticals Limited
See it. Treat it.
Pharmaceutical Manufacturing
North Melbourne, AU
1,203 employees
Founded 2015
4 public signals
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Headquartered in Melbourne, Australia, Telix operates internationally and is listed on the ASX and Nasdaq under the ticker TLX.
Verified activity
Signals from Telix Pharmaceuticals Limited
4 published signals
Research & Knowledge
Telix Pharmaceuticals Limited published an article highlighting the potential for its PSMA PET imaging in the diagnostic landscape for prostate cancer and reducing the burden for patients and healthcare professionals.
Reported by Richard Harrop
Legal & Regulatory
Telix Pharmaceuticals Limited positively engaged with the U.S. FDA on a New Drug Application (NDA) pathway that would support new product reimbursement and broaden patient access to ⁶⁸Ga-PSMA-PET imaging.
Reported by Telix Pharmaceuticals Limited
Research & Knowledge
Telix Pharmaceuticals Limited completed enrollment in the Phase 3 BiPASS study evaluating Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting.
Reported by Telix Pharmaceuticals Limited
People
Telix Pharmaceuticals Limited appointed David Gill as Chair of the Board.
Reported by Telix Pharmaceuticals Limited